Clinical trials: Botulinum Toxin, Type A
- Condition Botulinum Toxin, Type A
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Glabellar Lines
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Hyperfunctional facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05013424
- Testing
- Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Allergan
Glabellar Rhytides
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.
- Trial name
- NCT01814670
- Testing
- botulinum toxin Type A
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Allergan
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
- Trial name
- NCT01313299
- Testing
- Botulinum toxin type A
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 243 people
- Sponsor
- Ipsen
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan
Spasmodic Torticollis
Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia
The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck
- Trial name
- NCT00432341
- Testing
- botulinum toxin type A
- Where
- 3 sites in Argentina, Australia and 1 more
- Volunteers
- 54 people
- Sponsor
- Allergan
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Urinary Incontinence
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are…
- Trial name
- NCT02072928
- Testing
- botulinum toxin Type A
- Where
- 6 sites in Belgium
- Volunteers
- 55 people
- Sponsor
- Allergan
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
- Trial name
- NCT03786770
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Revance Therapeutics, Inc.
Masseter Muscle Prominence
BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT04073303
- Testing
- Botulinum Toxin Type A
- Where
- 21 sites in Canada, China and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie
Wrinkles
Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles
Single-centre, controlled, randomized, evaluator-blinded, bilateral (split-face) comparison study in subjects with moderate to severe forehead wrinkles.
- Trial name
- NCT01014871
- Testing
- Botulinum Toxin Type A - Azzalure, Botulinum Toxin Type A - Vistabel
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Galderma R&D
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Depressive Disorder, Major
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.
- Trial name
- NCT02116361
- Testing
- onabotulinumtoxinA, Normal Saline
- Where
- 35 sites in United States
- Volunteers
- 258 people
- Sponsor
- Allergan
Glabellar Lines
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
The purpose of the protocol is to demonstrate the safety and the efficacy of a single injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex (BTX A HAC NG) to improve the appearance of…
- Trial name
- NCT02493946
- Testing
- Botulinum toxin type A
- Where
- 24 sites in France, Germany and 1 more
- Volunteers
- 600 people
- Sponsor
- Ipsen
Glabellar Frown Lines
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum…
- Trial name
- STAR (NCT05277337)
- Testing
- Alluzience, powder BoNT-A (BOTOX/Vistabel)
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Galderma R&D
Masseter Muscle Hypertrophy
Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).
- Trial name
- NCT02010775
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 14 sites in Australia, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Allergan
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Lateral Canthal Lines
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
- Trial name
- NCT03911102
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Revance Therapeutics, Inc.